Anterior uveitis after treatment of age-related macular degeneration with ranibizumab and bevacizumab: Uncommon complication

Clinical Ophthalmology

Volumn 6, Issue 1, 2012, Pages 1201-1205

  Damasceno, Nadyr ^a   Horowitz, Soraya ^a   Damasceno, Eduardo ^b  

^a Hospital Naval Marcilio Dias   (Brazil)

^b FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

Anterior uveitis; Antiangiogenic agent; Bevacizumab; Complications; Ocular inflammatory process; Ranibizumab

Indexed keywords

BEVACIZUMAB; CORTICOSTEROID; CYCLOPLEGIC AGENT; RANIBIZUMAB;

AGED; ANTERIOR EYE CHAMBER; ARTICLE; BIOMICROSCOPY; CASE REPORT; CATARACT EXTRACTION; CONJUNCTIVAL HYPEREMIA; DRUG WITHDRAWAL; FEMALE; HUMAN; INTRAOCULAR PRESSURE; IRIDOCYCLITIS; KERATITIS; LENS IMPLANT; OPTICAL COHERENCE TOMOGRAPHY; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA MACULA AGE RELATED DEGENERATION; RETINOGRAPHY; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

EID: 84930472171     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S31239     Document Type: Article

References (5)

1. Day S, Acquah K, Mruthyunjaya P, Grossman DS, Lee PP, Sloan FA. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration. Am J Ophthalmol. 2011;152(2):266-272.
2. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006;90(11):1344-1349.
3. Gulati N, Forooghian F, Lieberman R, Jabs AD. Vascular endothelial growth factor inhibition in uveitis: a systemic review. Br J Ophthalmol. 2011;95:162-165.
4. Sato T, Emi K, Ikeda T, et al. Severe intraocular inflammation after intravitreal injection of bevacizumab. Ophthalmology. 2010;117(3): 512-513.
5. Wickremasinghe SS, Michalova K, Gilhotra J, et al. Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age related macular degeneration. Ophthalmology. 2008;115(11):1911-1915.